Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corporation (DVAX) delivers innovative vaccine solutions through cutting-edge immunological research and strategic commercialization. This news hub provides investors and healthcare professionals with essential updates on the biopharmaceutical leader's clinical developments, regulatory milestones, and market activities.
Track all critical DVAX updates in one place: Access press releases covering vaccine trial progress, FDA decisions, financial results, and partnership announcements. Our curated feed includes updates on HEPLISAV-B commercialization, CpG 1018 adjuvant applications, and pipeline developments across infectious disease and cancer immunotherapy programs.
Key coverage areas: Regulatory submissions for new vaccine candidates, quarterly earnings reports, manufacturing expansions, and scientific presentations. Content is rigorously verified to ensure accuracy for both professional investors and those monitoring public health advancements.
Bookmark this page for continuous access to Dynavax's official communications and analysis of strategic initiatives shaping the future of preventive healthcare. Check regularly for developments impacting vaccine accessibility and immunological innovation.
Dynavax Technologies (NASDAQ: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, after U.S. market close. The company will host a conference call and audio webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.
Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18 and older, and CpG 1018 adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.
Dynavax Technologies (NASDAQ: DVAX) has filed definitive proxy materials for its June 11, 2025 Annual Meeting, urging stockholders to vote for its four director nominees on the GOLD proxy card. The company highlights its strong performance, including 267% total stockholder returns over five years and record HEPLISAV-B® results, with net product revenue growing from $36M in 2020 to $268M in 2024.
The company is executing a balanced strategy focusing on HEPLISAV-B® commercialization and pipeline development, supported by a $200 million share repurchase program, of which $128.8M has been executed in Q1 2025. Dynavax expects 2025 HEPLISAV-B® net product revenue of $305-325M and projects the U.S. hepatitis B vaccine market to reach $900M by 2030.
The proxy battle involves Deep Track Capital, which seeks to replace four independent directors. Dynavax argues that Deep Track's proposals, including increasing share repurchases to $400M and focusing solely on HEPLISAV-B®, would be value-destructive for shareholders.
Deep Track Capital, owning approximately 14.34% of Dynavax Technologies (NASDAQ: DVAX) shares, has announced that DVAX's Board rejected their latest settlement proposal. The proposal included appointing Deep Track nominees Brett Erkman and Donald Santel to the Board, removing two long-tenured directors, and rebalancing board classes.
Deep Track expressed disappointment with the Board's rejection and unwillingness to negotiate, characterizing it as entrenchment. As the second-largest shareholder, Deep Track emphasized their commitment to pursuing changes they believe necessary for all stakeholders, including the eventual elimination of Hepatitis B focus.
The investment firm remains open to discussions but is prepared to continue their push for board changes at the 2025 Annual Meeting, where they have nominated four candidates.
Dynavax Technologies (DVAX) has filed preliminary proxy materials for its 2025 Annual Meeting, highlighting record operational and financial performance. The company's Board nominated four independent directors for reelection while emphasizing their successful strategy that delivered approximately 300% total stockholder returns over the past five years.
HEPLISAV-B® achieved record revenues of $268 million in 2024 with 44% U.S. market share, projecting $305-325 million in net product revenue for 2025. The company has generated about $950 million in revenue from COVID-19 pandemic-related business development.
The filing addresses ongoing engagement with Deep Track, which seeks Board control to implement what Dynavax describes as a short-term focused plan. Deep Track advocates for focusing solely on HEPLISAV-B commercialization and leveraging debt for immediate capital returns, which the current Board opposes as potentially risking long-term value creation.
Deep Track Capital, owning 14.34% of Dynavax Technologies (NASDAQ: DVAX), has sent a letter to the company's Board expressing concerns about capital allocation and governance. The letter highlights strong shareholder support for Deep Track's position and criticizes the Board's recent decision to issue $265 million in convertible notes instead of using available cash.
The investment firm nominated four candidates for the Board election at the 2025 Annual Meeting, seeking to improve corporate strategy and governance. Deep Track emphasizes that DVAX stock has risen 34% since their involvement in October 2024, while the biotech sector indices declined. They dispute the company's claim that they seek board control, noting they aim for four seats on a nine-member board.
The letter criticizes the Board's defensive tactics and highlights widespread shareholder support for having Deep Track representation, focusing on Heplisav's potential, and improving capital allocation strategies.
Dynavax Technologies (DVAX) has announced a significant debt refinancing initiative and share repurchase program. The company will issue $225 million in 2.0% Convertible Senior Notes due 2030, comprising an exchange for approximately $185 million of existing 2.50% Convertible Senior Notes due 2026 and $40 million in new notes.
The new notes will have an initial conversion price of $18.21 per share, representing a 30% premium over the March 5, 2025 closing price. The company will repurchase about $8 million of common stock and expects to receive $46.5 million from unwinding certain capped call derivatives.
This refinancing extends debt maturity, lowers capital costs, and reduces the total shares underlying the 2026 Notes by nearly 25%. Approximately $40 million of the 2026 Notes will remain outstanding with unchanged terms.
Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has announced its participation in two major upcoming investor conferences:
- TD Cowen 45th Annual Healthcare Conference on March 4 at 1:10 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on March 11 at 10:00 a.m. ET
The company will provide webcasted presentations accessible through their investor relations website. Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18+, and CpG 1018 adjuvant, used in HEPLISAV-B and various COVID-19 vaccines.
Dynavax Technologies (DVAX) reported strong financial results for Q4 and full year 2024, with HEPLISAV-B net product revenue growing 26% year-over-year to $268.4 million. The company's Q4 revenue reached $71.1 million, up 39% from the previous year.
Key highlights include:
- HEPLISAV-B U.S. market share increased to 44% by end of 2024
- Full year 2024 GAAP net income of $27.3 million ($0.21 per share)
- Cash position of $713.8 million as of December 31, 2024
- Adjusted EBITDA of $51.9 million for 2024, up 329% year-over-year
For 2025, Dynavax expects HEPLISAV-B net product revenue between $305-325 million and adjusted EBITDA of at least $75 million. The company plans to complete its $200 million share repurchase program and anticipates top-line results from its Phase 1/2 shingles vaccine trial in Q3 2025.
Dynavax Technologies (DVAX) has responded to Deep Track Capital's nomination of four board candidates, highlighting its strong execution and value creation strategy. The company reported record HEPLISAV-B revenue in 2024 with 26% year-over-year growth and expects to achieve 60% market share by 2030.
The company maintains a strong financial position with $714 million in cash as of year-end 2024 and has implemented a $200 million share repurchase plan, with $100 million already executed through an accelerated program. Dynavax recently secured a $30 million contract with the U.S. Department of Defense for its plague vaccine program and is advancing its shingles vaccine program.
The board has initiated refreshment changes, including appointing two new independent directors and planning board declassification. Despite multiple settlement attempts with Deep Track, negotiations have been unsuccessful, with Deep Track seeking board control without paying a control premium.
Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on vaccine development, has scheduled its fourth quarter and full year 2024 financial results announcement for February 20, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.
Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and Great Britain for hepatitis B virus prevention in adults 18 and older, and CpG 1018 adjuvant, used in HEPLISAV-B and various COVID-19 vaccines.
